All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The ALL Hub has previously reported results from the phase II ITCC-059 study (EudraCT:2016-000227-71), outlining the safety and efficacy of inotuzumab ozogamicin (InO) as a single agent in pediatric patients with relapsed/refractory B-cell lineage acute lymphoblastic leukemia.
Here, we summarize results from the phase Ib analyses of the ITCC-059 trial investigating InO combined with chemotherapy, published by Pennesi et al.1 in Haematologica.
Visual abstract | Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia
The ALL Hub is pleased to present a visual abstract representing key data from the phase II ITCC-059 trial...
Inotuzumab ozogamicin effective for the treatment of newly diagnosed older patients and pediatric patients with R/R BCP-ALL – results from two studies
Inotuzumab ozogamicin (InO) is an antibody–drug conjugate composed of an anti-CD22 antibody linked...
Subscribe to get the best content related to ALL delivered to your inbox